{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"title":"RECIST 1.1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"title":"mRECIST 1.1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"description":"Percentage of participants with confirmed and unconfirmed, complete and partial, defined by RECIST 1.1 and mRECIST for Pleural Tumors","groups":[{"description":"NEOADJUVANT: Patients receive atezolizumab IV over 30-60 minutes, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 2 hours on day 1. Cycles repeats every 21 days for 4 cycles in the absence of disease progression or unexpected toxicity.\n\nSURGERY: Within 21-90 days after completion of neoadjuvant therapy, patients undergo extrapleural pneumonectomy (EPP) or pleurectomy/decortication (PD). Patients who undergo EPP will then undergo radiation therapy.\n\nMAINTENANCE: Within 90 days after completion of either PD or radiation (post-EPP), patients receive atezolizumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 1 year in the absence of disease progression or unexpected toxicity.","id":"OG000","title":"Treatment (Chemotherapy, Surgery +/- RT, Maintenance)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Eligible and evaluable participants with measurable disease. 14 participants had measurable disease according to the RECIST which measures lesions from an x-ray, CT, or MRI. 22 participants had measurable disease according to the mRECIST which measures lesions as the sum of 6 CT cuts.","reportingStatus":"POSTED","timeFrame":"Duration of treatment and follow-up until death or 3 years post Step 1 registration.","title":"Response Rate (RR)","type":"SECONDARY","unitOfMeasure":"Participants"}